Abbott Launches SimpleScreen CRC: Advanced Screening for Colorectal Cancer
Abbott has unveiled the SimpleScreen CRC, a blood-based screening test for colorectal cancer, aimed at average-risk adults aged 45 and older in the U.S., marking a significant expansion of its cancer screening options.
The introduction of SimpleScreen CRC signifies Abbott's strategic efforts to broaden the accessibility of colorectal cancer screening methods in a country where the disease ranks as the second deadliest cancer. Given that a significant portion of the eligible population has not yet undergone screening, offering varied options becomes crucial. The American Cancer Society (ACS) advocates stool-based tests and visual examinations as primary screening methods. However, with many adults either refusing or unable to complete these procedures, the SimpleScreen CRC provides an acceptable alternative. Dr. Folasade May of UCLA Health underscores the importance of variety in screening methods to address patient reluctance and facilitate engagement.
Test Mechanics and Efficacy
The SimpleScreen CRC identifies cancer signals through circulating cell-free DNA detected in a blood sample. Its efficacy was rigorously evaluated in the PREEMPT CRC study, which involved over 48,000 individuals, ensuring a comprehensive assessment of its capabilities. The results were promising, showing the test accurately identified about 80% of colorectal cancers and avoided false positives in 90% of individuals without significant precancerous conditions, offering a reliable alternative for those hesitant about traditional methods.
Insurance Coverage and Patient Support
Recognizing the financial aspects of healthcare, Abbott ensures that the SimpleScreen CRC is reimbursable under Medicare with no out-of-pocket costs for Medicare Part B holders, though Medicare Advantage members might have additional costs depending on their specific plan. Abbott also provides extensive patient support, including blood draw coordination, reminders, bilingual communication, and insurance guidance, facilitating a smooth process from testing to follow-up. A positive SimpleScreen CRC result necessitates a follow-up colonoscopy, aligning with ACS guidelines.
| Test Type | Screening Method | Patient Coverage |
|---|---|---|
| SimpleScreen CRC | Blood-based, detects cell-free DNA | Medicare-covered, potential costs for Advantage plans |
| Cologuard Plus | Stool-based, detects DNA mutations | Varies by plan, generally covered |
Jake Orville, Abbott's senior vice president for cancer diagnostics, highlights the ongoing commitment to connecting individuals with suitable screening options, promoting the transition from initial blood tests to more comprehensive procedures like the Cologuard Plus and colonoscopies.